The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
Analyst rates Hims & Hers Health a Strong Buy: $23.8 implies roughly 20% upside toward a 15% annual return, led by international expansion.
The company generated strong growth last quarter, but its bottom line didn't look nearly as impressive.
Revenue is increasing, but so are its operating expenses.
Hims stock zoomed higher on an HHS push to legalize six peptides. It could be just the beginning of a healthcare overhaul.
Hims & Hers Health, Inc., is a Hold: Q3 growth excluding Eucalyptus was 26%. Click for this HIMS stock earnings update and see if it is right for you.
The firm kept a Sector Weight rating, saying it wants more signs of a growth inflection
By Kanishka Singh WASHINGTON, Nov 10 (Reuters) - Five US states have joined the Federal Trade Commission in a lawsuit that alleges telehealth company Hims & Hers Health engaged in deceptive and
Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. Read more on HIMS stock here.
Hims & Hers Health (NYSE:HIMS) has appointed neuroscientist Dr. Andrew Huberman to its Board of Directors. Dr. Huberman will also serve as a scientific advisor to Hims & Hers Health, guiding neuroscience and wellness related product thinking. He will act as a brand and marketing advisor, bringing experience from his global audience and health focused podcast to consumer outreach. Dr. Andrew Huberman joining the Hims & Hers Health board and advisory group sits against broader themes our...
Revenue rose 49% to $890.4 million, but gross margin collapsed to 57% from 74% and full-year profit guidance moved lower.
Hims & Hers shares fall 14% after Q3 revenue of $890.3 million and EPS of -$0.14 miss estimates; 2026 revenue guidance narrows to $3.13B-$3.15B.
Hims & Hers Earnings Disaster as Costs Soar and Outlook Falls Far Short
Subscribers fell by 100,000 from the previous quarter, prompting concerns about near-term growth.
Hims & Hers: 22.7x adjusted EBITDA looks costly with gross margin at 57.2%; a 233-million-share scenario implies 46% downside to $12.45. Click for more on HIMS stock.
Hims & Hers plans to launch Peptides+ offering later this month with glutathione, NAD, sermorelin, and B-12; BPC-157 and TB-500 await regulatory nod. Read more here.
This is the newest page. Registered accounts read further back.